The Royal Marsden Cancer Charity hails Sheikha Jawaher Al Qasimi's role in advancing precision medicine for cancer treatment
One of only two UK labs selected by NHS England to evaluate long-read whole genome sequencing for clinical application.
Enhancing lung cancer genetic mutation analysis using 'Liquid Biopsy' technology
Capacity has been doubled to deliver an additional ,000 genetic tests monthly
Actively participating in clinical trials for DNA-based personalised therapies
The Royal Marsden is a specialist cancer centre that brings together world class researchers and dedicated clinical teams providing expert compassionate care
Sharjah: The Royal Marsden Cancer Charity; which supports the work of The Royal Marsden; has commended the significant support of Her Highness Sheikha Jawaher bint Mohammed Al Qasimi, Wife of the Ruler of Sharjah and Founder/Royal Patron of the Friends of Cancer Patients (FoCP). Its annual report highlighted her contributions to advancing cancer research, particularly through initiatives over the past five years that have accelerated progress at the Sharjah Clinical Genomics Laboratory within the National Institute for Health and Care Research (NIHR) Centre for Molecular Pathology (CMP); housed within The Royal Marsden in the UK. These efforts have greatly enhanced faster delivery of precise diagnoses and cutting-edge personalised treatments for patients.
The report underscored that Her Highness's support has empowered the lab's scientific team to fast-track diagnostics and treatments, bringing hope to thousands of patients. This was achieved through the introduction of state-of-the art facilities to the Sharjah Clinical Genomics Laboratory; including the UK's first robotic genome testing facility; and bringing together world experts in molecular pathology, bioinformatics, translational research.
A humanitarian grant has been driving rapid progress
The Sharjah Laboratory was launched in 2018 as a humanitarian initiative by Her Highness Sheikha Jawaher Al Qasimi, who donated £500,000 to support its establishment within the CMP at The Royal Marsden in the UK. This donation reflects Her Highness's strong belief that investing in scientific research is foundational in the fight against cancer and that such research can make a genuine global impact, benefiting patients far beyond the institution itself.
Founded in 1851, The Royal Marsden in London is the world's first and most renowned cancer centers. It specialises in the diagnosis, treatment, and research of all types of cancer, with a highly experienced medical team and a dedicated department for paediatric and adolescent care. The hospital serves more than 50,000 patients annually and works in close collaboration with its academic partner, The Institute of Cancer Research, London, cementing its position as a global leader in cancer treatment innovation.
Recent advancements enhancing cancer care
Recent advancements at the CMP are enhancing cancer care and were reflected in a comprehensive report. The 'Marsden360' service, developed in partnership with Guardant Health, uses liquid biopsy (a blood test for cancer) to identify the genetic changes in DNA, allowing patients to be matched to targeted treatments. The testing was offered as part of an NHS England national study for patients with suspected late-stage lung cancer, as well as providing a commissioned NHS ctDNA service to guide treatment decisions for eligible patients with suspected late-stage breast cancer.
The report also noted the Sharjah Clinical Genomics Laboratory is on track to become the first facility in the UK to offer fully automated genomic testing, with the capacity to conduct 5000 tests monthly. This is being achieved through collaboration with Automata, a global biotech company providing robotic automation solutions to the life sciences industry. The advancement has improved early detection of genetic mutations and enabled proactive care for high-risk cancer patients.
Cutting-edge technology includes the Nanopore PromethION device for precise long-read DNA sequencing, already analyzing 110 whole genomes to yield new insights for treatment development. The CMP also plays a vital role in key clinical trials like 'ENABLE-NGS', 'PREVAIL', and 'ICED' (targeting leukemia, lung, and rare cancers), 'SIGNIFIED' (offering annual scans for Li-Fraumeni Syndrome), 'INOVATE' (blood-based monitoring for head/neck cancers), and 'RECUT Plus' (studying radiotherapy resistance).
Further amplifying its impact, the lab contributed to over 24 peer-reviewed studies in 2024, presented at major conferences like ESMO and ASCO, exploring molecular profiling to redefine cancer risk and reshape treatment strategies.
A UAE humanitarian vision for the world
The Sharjah Clinical Genomics Laboratory reflects the UAE's vision of investing in human potential and scientific research, transforming humanitarian efforts into tangible impact in patients' lives. It serves as a prime example of successful collaboration between philanthropy and science, through which Sharjah has become an active partner and contributor to the future of genomic medicine worldwide.
The laboratory's success in the UK exemplified the vision and commitment of Her Highness Sheikha Jawaher Al Qasimi commitment to supporting cancer patients. Her Highness's efforts have directly supported several specialised institutions such as Children's Cancer Hospital Egypt 57357, the Children's Cancer Center of Lebanon (CCCL), the National Cancer Institute in Egypt (Sheikha Jawaher Al Qasimi Building), and the Union for International Cancer Control's (UICC) Fund for Childhood Cancer Patients. Through these efforts, Her Highness Sheikha Jawaher Al Qasimi champions a UAE global humanitarian mission that transcends borders.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Emirates 24/7
3 hours ago
- Emirates 24/7
British scientists develop new genetically modified bacterial strain
British scientists have developed a new strain of Escherichia coli with a genetically recoded genome. According to researchers from the Medical Research Council Laboratory of Molecular Biology, the genetic code is known to consist of triplets of nucleotides, called codons, responsible for synthesising proteins essential for life. In nature, there are 64 codons, although only 21 are required to produce 20 amino acids plus a stop signal. The newly developed strain now contains just 57 codons instead of the usual 64. This development has resulted in the most compact genome among known organisms. By reducing the number of codons, scientists have freed part of the DNA code, creating the potential to design and use novel amino acids not found in nature. In 2019, scientists created the Syn61 strain with 61 codons, which required 18,000 DNA modifications. In the latest study, a team led by synthetic biologist Wesley Robertson carried out more than 100,000 modifications, producing a new strain named Syn57. Robertson noted that Syn57 currently grows four times slower than standard Escherichia coli, but researchers believe further adjustments could improve its growth rate. The earlier Syn61 strain is already used to produce more reliable medicines. Robertson described the new strain as having a radically recoded genome, exemplifying the ability of synthetic biology to transfer genetic sequences into 'realms inaccessible to natural life'. The significance of this engineered bacterium lies in its potential to help create bacteria with unique virus-resistant properties, opening new horizons for the development of innovative medicines and advanced materials. It marks an important step forward in the fields of synthetic biology and genetic engineering. Follow Emirates 24|7 on Google News.
Khaleej Times
7 hours ago
- Khaleej Times
NMC Healthcare hosts 3-day series supporting MOHAP's Hayat initiative for World Organ Donation Day
This initiative aims to raise public awareness about the critical importance of organ donation and encourage organ donor registrations in the UAE NMC Healthcare ('NMC') is proud to host three days of educational sessions on organ donation, starting today, 13 August 2025, in observance of World Organ Donation Day. This initiative aims to raise public awareness about the critical importance of organ donation and encourage organ donor registrations in the UAE. The educational sessions are open to the public and will take place at five of NMC Healthcare's major hospitals in Sharjah, Dubai, and Abu Dhabi. The campaign is organised in collaboration with Hayat - the UAE's National Program for Donation and Transplantation of Human Organs and Tissues, led by the UAE's Ministry of Health & Prevention ('MOHAP'), which encourages UAE residents over the age of 18 to register as organ donors. Hayat follows international standards and best practices to promote safe and effective organ donation. Dr. Zaka ullah Khan, chief clinical officer at NMC Healthcare said: 'We are honoured to join forces with Hayat to bring attention to organ donation and share information about how organ donation transforms lives – from patients with chronic kidney failure, to those awaiting liver, heart, or lung transplants. We hope to help inspire more people to contribute to this life-saving cause.' NMC hospitals across the country will host a series of educational sessions which explain: NMC Healthcare encourages eligible individuals to learn more about organ donation and consider registering as donors through this life-saving campaign. For more information and to register as an organ donor, please visit the organ donation booths from 13-15 August, 2025, between 8:00am – 5:00pm at:
Emirates 24/7
9 hours ago
- Emirates 24/7
Al Jalila Foundation Supports 60 Organ Transplant Patients
Al Jalila Foundation, the philanthropic arm of Dubai Health, announced that it has contributed to saving the lives of 60 patients by supporting organ transplant surgeries as part of the first and second editions of the Your Donation Saves Lives campaign. The announcement coincides with World Organ Donation Day, observed annually on 13 August, and reflects the Foundation's long-term commitment to supporting patients with organ failure and fostering a culture of organ donation as a humanitarian value. Since its launch in April 2021, the campaign has supported 60 transplant procedures, including 53 kidney transplants and 7 liver transplants. Among these are 24 children with kidney failure and 5 children with liver failure. As part of this program, the Foundation continues to support more than 65 patients with life-saving transplants, who are unable to access or afford specialized care. These efforts are aligned with the goals of HAYAT, the National Program for Organ and Tissue Donation and Transplantation and are carried out in partnership with Dubai Health's integrated academic health system. From Campaign to Permanent Program Dr. Amer Al Zarooni, CEO of Al Jalila Foundation, announced that the Your Donation Saves Lives campaign has now evolved into a permanent initiative under the Foundation's A'awen program, which provides financial assistance to patients in need of critical medical treatment across the UAE, a step that aligns with Dubai Health's commitment, 'Patient First'. 'On World Organ Donation Day, we reaffirm our commitment to supporting patients with organ failure and extend our heartfelt thanks to the generous donors, individuals and institutions alike, who contributed to both the first and second editions of the Your Donation Saves Lives campaign. Their support represents a powerful model of human solidarity, with the first edition alone helping to fund nearly 30% of all organ transplants performed in Dubai,' said Dr. Al Zarooni. He also extended his appreciation to living organ donors and to the families of deceased donors, saying: 'Your compassion has given others a second chance at life. We thank you for your extraordinary generosity.' Ensuring Safe, Successful Transplants Dr. Ashraf Al Hinnawi, Consultant Transplant Surgeon at Dubai Health, explained that the medical team works collaboratively to thoroughly evaluate both the donor and the recipient before transplantation, ensuring the highest possible long-term success rates. 'We conduct comprehensive assessments of kidney function and immune compatibility between the donor and recipient, along with detailed medical and surgical evaluations that include lab tests and imaging studies to ensure the success of the transplant. We also follow up with patients regularly after the procedure to ensure adherence to the treatment plan and to closely monitor kidney function.' Regarding living donors, Dr. Al Hinnawi noted that they undergo meticulous evaluations, including assessment of the kidneys, functional testing, and screening for any infectious or cancerous conditions, in addition to psychological and social assessments. He added that all cases are reviewed by a multidisciplinary medical committee to determine donor eligibility, ensuring the highest levels of safety for both donor and recipient. A Lifeline for Patients in Need Al Jalila Foundation continues to welcome donations through A'awen, offering individuals and organizations the opportunity to fund life-changing programs that enhance well-being and provide essential medical care. The first edition of the campaign was launched in April 2021 in collaboration with Mohammed Bin Rashid University of Medicine and Health Sciences, the Islamic Affairs and Charitable Activities Department, and Emarat Al Youm newspaper. The second edition took place in September 2024 and concluded in December of the same year, as part of a collaboration between the Islamic Affairs and Charitable Activities Department, Al Jalila Foundation, and Emarat Al Youm newspaper. Transplant surgeries were conducted in partnership with Dubai Health's Dubai Hospital and Al Jalila Children's Hospital, alongside Mediclinic City Hospital and King's College Hospital London in Dubai. Stories of Hope Yousef's New Beginning Among the beneficiaries of the campaign, is the child Yousef Jashim, who underwent a kidney transplant with the support of Al Jalila Foundation. Yousef suffered from constant fatigue and recurring pain and was undergoing regular dialysis sessions that significantly affected his daily life and imposed strict dietary restrictions. When he turned fourteen, the doctors informed his family of the necessity of a kidney transplant as an essential step in his treatment journey. Al Jalila Foundation's support was instrumental, helping the family cover the cost of the surgery. Following the transplant, Yousef's life transformed. He regained his energy and no longer required dialysis. His mother expressed deep gratitude to Al Jalila Foundation, the medical teams involved in his care, and the wider community whose support helped save her son's life. Roula's Healing Journey Roula Tabba'a is also among the beneficiaries of the campaign, following a long journey with kidney failure. She underwent dialysis three times a week, which caused severe physical and emotional exhaustion. Her condition was first diagnosed in 2016, and she underwent several surgeries. Al Jalila Foundation covered the cost of her dialysis sessions and medical tests, eventually supporting her inclusion in the kidney transplant program. After years of waiting, Roula received a life-changing call from the medical team confirming that she had been approved for the procedure. Thanks to the dedication of the medical staff, the transplant was successful. Her life was completely transformed following the surgery, she no longer needed dialysis and regained her ability to move freely, travel, and live independently. Roula expressed her deep gratitude to Al Jalila Foundation, saying its support not only saved her life, but also restored hope and stability for her entire family.
